N-terminal propeptide of type III procollagen for predicting diastolic dysfunction in patients with myocardial infarction and preserved ejection fraction

Aim. To study changes in the level of fibrotic scarring marker — the N-terminal propeptide type III procollagen (PIIINP) and structural and functional parameters with the assessment of diastolic function in patients a year after ST segment elevation myocardial infarction (STEMI) and preserved left ventricle (LV) contractility.

Material and methods. At first, the study included 120 (100%) STEMI patients. Next, patients with an LV ejection fraction (EF) ≥50% were selected. The final analysis included 86 STEMI patients. Upon hospitalization, the patients underwent routine diagnostic tests, coronary angiography with stenting of culprit artery. Echocardiography and determination of venous blood PIIINP and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels was on the 1^st (time point 1) and 12^th day (time point 2) of disease and after a year (time point 3). To compare the obtained values of fibrotic scarring markers, a control group was formed, including 20 (100%) healthy volunteers, identical in age and sex with the studied sample.

Results. On the first day of MI, 25 (29,1%) patients with signs of diastolic dysfunction (DD) were identified among those with preserved LVEF. After 1 year, the number of such patients increased by 10% (n=9). Initially increased (relative to the control group) concentration of PIIINP on the first day (311,2 [220,1; 376,3] ng/ml) decreased by the 12^th day (223,3 [195,3; 312,1] ng/ml) and returned to the initial values a year after the MI (312,6 [228,0; 383,8] ng/ml). The NT-proBNP concentration during the hospitalization period did not exceed the reference values and did not differ between 1 and 2 time points (p=0,127). One year later, the NT-proBNP concentration significantly exceeded the values of the previous determinations and amounted to 124,4 pg/ml (p=0,043). According to the ROC analysis, with a PIIINP ≥387,8 ng/ml on the first day, the risk of DD increases (p=0,050, sensitivity, 84,62%, specificity, 55,56%) within a year after STEMI with preserved LVEF.

Conclusion. The threshold of PIIINP (≥387,8 ng/ml) was established for the first day of MI, at which the risk of DD increases one year after the index event. An increase in NT-proBNP concentration one year after STEMI indicates the progression of heart failure.

1. Titova AL, Saiganov SA. Diastolic function of the left ventricle in patients with coronary heart disease who underwent coronary artery bypass surgery. Russian family doctor. 2014;18(3):10-7. (In Russ.)

2. Bartosh FL, Bartosh LF, Adonina TS. Features of diastolic function of the left ventricular myocardium in patients with hypertension with atrial fibrillation. Arterial hypertension. 2012;18(2):142-7. (In Russ.) doi:10.18705/1607-419X-2012-18-2-142-147.

3. Shilov SN, Teplyakov AT, Yakovleva IL, and all. Clinical and pathogenetic relationship of chronic heart failure, type 2 diabetes mellitus and osteoporosis. Complex problems of cardiovascular diseases. 2018;7(1):6-13. (In Russ.) doi:10.17802/2306-1278-2018-7-1-6-1.

4. Weber K, Sun Y, Campbell S. Structural remodeling of the heart by fibrous tissue: Role of circulating hormones and locally produced peptides. Eur Heart J. 1995;16 Suppl N:12-8. doi:10.1093/eurheartj/16.suppl_n.12.

5. Karetnikova VN, Kashtalap VV, Kosareva SN, Barbarash OL. Myocardial fibrosis: current aspects of the problem. Therapeutic Archive. 2017;89(1):88-93. (In Russ.) doi:10.17116/terarkh201789188-93.

6. Mareev VYu, Ageev FT, Arutyunov GP, et al. National recommendations of the OSSN, RKO and RNMOT for the diagnosis and treatment of CHF (fourth revision). J Heart Fail. 2013;14(7)(81):379-472. (In Russ.)

7. 7 Drapkina OM, Zyatenkova EV. Markers of fibrosis in patients with metabolic syndrome. Russian Medical J. 2016;26:1727-31. (In Russ.)

8. Belenkov YuN, Oganov RG. Cardiology: national leadership. M.: GEOTAR-Media, 2012. р. 535. (In Russ.) ISBN: 978-5-9704-2733-0.

9. Matyal R, Skubas NJ, Shernan SK, Mahmood F. Perioperative assessment of diastolic dysfunction. Anesth Analg. 2011;113(3):449-72. doi:10.1213/ANE.0b013e31822649ac.

10. Drapkina OM, Gegenava BB. Type III procollagen N-terminal propeptide as a possible serum marker of myocardial fibrosis in patients with type 2 diabetes. Cardiovascular Therapy and Prevention. 2018;17(3):17-21. (In Russ.) doi:10.15829/1728-8800-2018-3-17-21.

11. Drapkina OM, Zyatenkova EV. Assessment of the level of N-terminal collagen type III propeptide in patients with chronic heart failure and metabolic syndrome. Cardiovascular Therapy and Prevention. 2015;14(6):42-7. (In Russ.) doi:10.15829/1728-8800-2015-6-42-47.

12. Putyatin AN, Kim LB. Extracellular matrix of the heart and postinfarction reparative fibrosis (part 1). Vestnik SAFU. Series: Biomedical Sciences. 2016;4:54-66. (In Russ.) doi:10.17238/issn2308-3174.2016.4.54.

13. Kovar F, Knazeje M, Mokan M. Risk Stratification and Invasive Strategy in NSTE-ACS [Electronic Resource]. URL: http://cdn.intechopen.com/pdfs/19478/InTech-Risk_stratification_and_invasive_strategy_in_nste_acs.pdf (date access: 25.09.2013).

14. Mrikaev DV. Diastolic dysfunction of the left ventricle in patients with heart failure. Creative cardiology. 2017;11(2):145-58. (In Russ.) doi:10.24022/1997-3187-2017-11-2-145-158.